Cejemly Sugemalimab Injection

1. Indications and Usage
Non-Small Cell Lung Cancer (NSCLC):
Non-Squamous NSCLC: Indicated in combination with pemetrexed and carboplatin for the first-line treatment of patients with metastatic non-squamous NSCLC who are negative for EGFR gene mutations and ALK gene rearrangements.
Squamous NSCLC: Indicated in combination with paclitaxel and carboplatin for the first-line treatment of patients with metastatic squamous NSCLC.
Stage III NSCLC: Indicated for the treatment of patients with unresectable Stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy.
2. Dosage and Administration
Route of Administration:
Intravenous Infusion ONLY. Do not administer as an IV push or bolus.
Recommended Dosage:
Dose: 1200 mg administered intravenously every 3 weeks.
Duration: Infuse over 60 minutes or longer. Continue until disease progression or unacceptable toxicity.
Preparation:
Dilute the required volume into a sterile infusion bag containing 0.9% Sodium Chloride Injection (250 mL).
3. Mechanism of Action
PD-L1 Blockade:
Sugemalimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds directly to PD-L1.
Immune Activation:
It inhibits the interaction between PD-L1 and its receptors (PD-1 and B7.1) on T cells and antigen-presenting cells, thereby blocking immunosuppressive reactions, including anti-tumor immune responses.
4. Safety and Warnings
Immune-Mediated Adverse Reactions:
Sugemalimab can cause severe and life-threatening immune-mediated adverse reactions in any organ system, including pneumonitis, hepatitis, nephritis, and endocrinopathies (e.g., hypothyroidism). Monitor patients closely.
Embryo-Fetal Toxicity:
May cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least 6 months after the last dose.
5.Adverse Reactions
Most Common:
Fatigue, rash, hyperglycemia, musculoskeletal pain, abdominal pain, hypothyroidism, and elevated transaminases (ALT/AST).
6. Drug Interactions
Immunosuppressants:
Avoid the use of systemic corticosteroids and other immunosuppressive drugs prior to initiating Sugemalimab, as they may interfere with its pharmacodynamic activity.
Metabolic Interactions:
As a monoclonal antibody, Sugemalimab is not metabolized by CYP450 enzymes.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Sugemalimab.
Storage:
Store in a refrigerator at 2-8°C. Do not freeze or shake. Protect from light.